Cloned (Comment) | Organism |
---|---|
human rhinovirus type 2 | Human rhinovirus sp. |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
1,10-phenanthroline | - |
Human rhinovirus sp. | |
3,4-dichloroisocoumarin | - |
Human rhinovirus sp. | |
antipain | eIF-4gamma as substrate in HeLa cell extracts; human rhinovirus | Human rhinovirus sp. | |
Ca2+ | 50 mM, weak | Human rhinovirus sp. | |
chymostatin | eIF-4gamma as substrate in HeLa cell extracts; human rhinovirus | Human rhinovirus sp. | |
Co2+ | 0.05 mM | Human rhinovirus sp. | |
Cu2+ | 0.05 mM | Human rhinovirus sp. | |
EDTA | at high concentration | Human rhinovirus sp. | |
Elastinal | eIF-4gamma as substrate in HeLa cell extracts; human rhinovirus | Human rhinovirus sp. | |
Hg2+ | 0.05 mM | Human rhinovirus sp. | |
iodoacetamide | strong | Human rhinovirus sp. | |
leupeptin | not | Human rhinovirus sp. | |
Mg2+ | 50 mM, weak | Human rhinovirus sp. | |
Mn2+ | 2 mM; weak | Human rhinovirus sp. | |
additional information | no inhibition by amastatin, bestatin, epiamastatin, foroxymithin, phosphoramidon, Nle-statine-Ala-statine and APMSF; no inhibition by trans-epoxysuccinyl-L-leucylamido(4-guanidino)-butane (i.e. E-64) | Human rhinovirus sp. | |
NEM | strong | Human rhinovirus sp. | |
tosyl-L-leucine-chloromethyl ketone | - |
Human rhinovirus sp. | |
tosyl-L-phenylalanine-chloromethyl ketone | weak | Human rhinovirus sp. | |
Zn2+ | 0.05 mM | Human rhinovirus sp. |
Metals/Ions | Comment | Organism | Structure |
---|---|---|---|
NaCl | activation, 0.15-1.25 M | Human rhinovirus sp. |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Human rhinovirus sp. | - |
serotypes 2 | - |
Purification (Comment) | Organism |
---|---|
partial | Human rhinovirus sp. |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
Arg-Arg-Asn-Thr-Gly-Pro-Ser-Asp-Met-Tyr-Val-His + H2O | peptide derived from poliovirus type 1 polyprotein, poor substrate | Human rhinovirus sp. | Arg-Arg-Asn-Thr-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met-Tyr-Val-His | - |
? | |
Arg-Pro-Ile-Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp-Met-Tyr-Val-His + H2O | i.e. synthetic peptide P7-P8', hydrolyzed with about the same relative efficiency compared to P8-P8' | Human rhinovirus sp. | Arg-Pro-Ile-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met-Tyr-Val-His | - |
? | |
Glu-Arg-Ala-Ser-Ile-Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp-Met-Tyr-Val-His + H2O | peptide derived from poliovirus type 1 polyprotein | Human rhinovirus sp. | Glu-Arg-Ala-Ser-Ile-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met-Tyr-Val-His | - |
? | |
Ile-Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp-Met-Tyr-Val-His + H2O | i.e. synthetic peptide P5-P8', poor substrate | Human rhinovirus sp. | Ile-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met-Tyr-Val-His | - |
? | |
Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp-Met-Tyr-Val-His + H2O | i.e. synthetic peptide P4-P8', poor substrate | Human rhinovirus sp. | Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met-Tyr-Val-His | - |
? | |
modified pentadecameric peptides + H2O | i.e. synthetic P8-P7' peptides, intermolecular specificity, changes at P2 and P1' are highly deleterious | Human rhinovirus sp. | ? | - |
? | |
additional information | no hydrolysis of some modified pentadecameric synthetic peptides P8-P7'(overview), synthetic peptides P3-P8', Arg-Lys-Gly-Asp-Ile-Lys-Ser-Tyr-Gly-Ile-Gly-Pro-Arg-Tyr-Gly-Gly, Asn-Val-Arg-Ala-Val-Lys-Asn-Val-Gly-Pro-Ser-Asp-Met-Tyr-Val-His, Asp-Val-Phe-Thr-Asn-Val-Gly-Pro-Ser-Ser-Met-Phe-Val-His | Human rhinovirus sp. | ? | - |
? | |
additional information | synthetic peptides with replacements of P1 or P1' residues with epsilon-amino caproic acid or statine | Human rhinovirus sp. | ? | - |
? | |
Pro-Arg-Ala-Ser-Met-Lys-Thr-Val-Gly-Pro-Ser-Asp-Met-Tyr-Val-His + H2O | poor substrate | Human rhinovirus sp. | Pro-Arg-Ala-Ser-Met-Lys-Thr-Val + Gly-Pro-Ser-Asp-Met-Tyr-Val-His | - |
? | |
Pro-Arg-Glu-Asn-Gly-Pro-Ser-Asp-Met-Tyr-Val-His + H2O | peptide derived from poliovirus type 1 polyprotein, poor substrate | Human rhinovirus sp. | Pro-Arg-Glu-Asn-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met-Tyr-Val-His | - |
? | |
Pro-Ile-Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp-Met + H2O | i.e. synthetic peptide P6-P5', hydrolyzed with 42% relative efficiency compared to P8-P8' | Human rhinovirus sp. | Pro-Ile-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met | - |
? | |
Pro-Ile-Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp-Met-Tyr + H2O | i.e. synthetic peptide P6-P6', hydrolyzed with 45% relative efficiency compared to P8-P8', smallest cleavable symmetric peptide | Human rhinovirus sp. | Pro-Ile-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met-Tyr | - |
? | |
Pro-Ile-Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp-Met-Tyr-Val + H2O | i.e. synthetic peptide P6-P7', hydrolyzed with 55% relative efficiency compared to P8-P8' | Human rhinovirus sp. | Pro-Ile-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met-Tyr-Val | - |
? | |
Pro-Ile-Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp-Met-Tyr-Val-His + H2O | i.e. synthetic peptide P6-P8' | Human rhinovirus sp. | Pro-Ile-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met-Tyr-Val-His | - |
? | |
Pro-Ile-Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp-Met-Tyr-Val-His + H2O | hydrolyzed with 70% relative efficiency compared to P8-P8' | Human rhinovirus sp. | Pro-Ile-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met-Tyr-Val-His | - |
? | |
Ser-Arg-Ala-Ile-Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp-Met-Tyr-Val-His + H2O | peptide derived from poliovirus type 1 polyprotein | Human rhinovirus sp. | Ser-Arg-Ala-Ile-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met-Tyr-Val-His | - |
? | |
Ser-Thr-Lys-Asp-Ile-Thr-Thr-Tyr-Gly-Phe-Gly-His-Gln-Asn-Lys-Ala + H2O | poor substrate | Human rhinovirus sp. | Ser-Thr-Lys-Asp-Ile-Thr-Thr-Tyr + Glys-Phe-Gly-His-Gln-Asn-Lys-Ala | - |
? | |
Thr-Arg-Pro-Ile-Ile-Thr-Thr-Ala-Gly + H2O | i.e. synthetic peptide P8-P1', poor substrate, smallest cleavable asymmetric peptide | Human rhinovirus sp. | Thr-Arg-Pro-Ile-Ile-Thr-Thr-Ala + glycine | - |
? | |
Thr-Arg-Pro-Ile-Ile-Thr-Thr-Ala-Gly-Pro + H2O | i.e. synthetic peptide P8-P2', hydrolyzed with about the same relative efficiency as P8-P8' | Human rhinovirus sp. | Thr-Arg-Pro-Ile-Ile-Thr-Thr-Ala + Gly-Pro | - |
? | |
Thr-Arg-Pro-Ile-Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp + H2O | i.e. peptide P8-P4' | Human rhinovirus sp. | Thr-Arg-Pro-Ile-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp | - |
? | |
Thr-Arg-Pro-Ile-Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp-Met + H2O | i.e. peptide P8-P5' | Human rhinovirus sp. | Thr-Arg-Pro-Ile-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met | - |
? | |
Thr-Arg-Pro-Ile-Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp-Met-Tyr + H2O | i.e. synthetic peptide P8-6' | Human rhinovirus sp. | Thr-Arg-Pro-Ile-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met-Tyr | - |
? | |
Thr-Arg-Pro-Ile-Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp-Met-Tyr-Val + H2O | i.e. synthetic peptide P8-7' | Human rhinovirus sp. | Thr-Arg-Pro-Ile-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met-Tyr-Val | - |
? | |
Thr-Arg-Pro-Ile-Ile-Thr-Thr-Ala-Gly-Pro-Ser-Asp-Met-Tyr-Val-His + H2O | i.e. synthetic peptide P8-P8' | Human rhinovirus sp. | Thr-Arg-Pro-Ile-Ile-Thr-Thr-Ala + Gly-Pro-Ser-Asp-Met-Tyr-Val-His | - |
? |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
7 | 8.5 | broad, synthetic peptide P8-P8' as substrate | Human rhinovirus sp. |
pH Minimum | pH Maximum | Comment | Organism |
---|---|---|---|
6 | 9.2 | about half-maximal activity at pH 6 and 9.2, synthetic peptide P8-P8' as substrate | Human rhinovirus sp. |
pH Stability | pH Stability Maximum | Comment | Organism |
---|---|---|---|
4 | 9 | 20 min, room temperature, stable in this range, 50% loss of activity at pH 3 and 10.2 | Human rhinovirus sp. |